Angel News

Angel News

Back to Homepage

23rd April 2018

Albion backed Orchard Therapeutics signs strategic deal with GSK

 

 

GSK and Orchard Therapeutics have announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programmes and access for patients. This acquisition strengthens Orchard’s position as a global leader in gene therapy for rare diseases. GSK will continue to invest in the development of its platform capabilities in cell and gene therapies, with a focus on oncology.

...

Register / Login now to read full story

In order to read the full story we need you to be registered with us, please click the links below to login or register.

Login / Register

Add a comment:

Name:

Email:

Comment:

Enter the characters in the image shown:



Back to Homepage